Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

Inclusion Criteria: 1. Voluntarily sign the informed consent form (ICF); 2. Male or female, over 18 years old; 3. Survival duration more than 3 months; 4. ECOG score ≤ 1 point; 5. Participants in Phase Ia (dose-escalation phase) are required to meet the following criteria: histologically or cytologically confirmed diagnosis of advanced malignant solid tumour; 6. Participants in Phase Ib (dose-expansion phase) and Phase II are required to meet the following criteria: Histologically or cytologically confirmed specific type advanced malignant solid tumours; 7. At least one measurable tumor lession according to RECIST v1.1; 8. Adequate organ and bone marrow function. Exclusion Criteria: 1. Has participated in another clinical study within 4 weeks prior to the first dose; 2. Other malignancies diagnosed within 5 years prior to the enrollment; 3. Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases; 4. Significant bleeding risk; 5. Presence of pleural effusion, peritoneal effusion, or ascites; 6. History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs; 7. Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence; 8. History of severe allergies, severe drug allergies (including unapproved investigational drugs); 9. History of organ transplantation or stem cell transplantation; 10. Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study; 11. Received chemotherapy, immunotherapy, biologic therapy, or other anti-tumor treatments within 4 weeks before enrollment; 12. Pregnant or breastfeeding female.